| First Author | Maeda YY | Year | 1996 |
| Journal | Immunogenetics | Volume | 43 |
| Issue | 4 | Pages | 215-9 |
| PubMed ID | 8575820 | Mgi Jnum | J:35330 |
| Mgi Id | MGI:82779 | Doi | 10.1007/BF00587302 |
| Citation | Maeda YY, et al. (1996) Two genes controlling acute phase responses by the antitumor polysaccharide, lentinan. Immunogenetics 43(4):215-9 |
| abstractText | Lentinan, a beta-1,6;1,3-glucan, is tumor-specific for transplantable mouse solid-type tumors and it also stimulates the production of acute phase proteins (APPs). The APP response to lentinan is of the delayed type (DT-APR) and differs from that to lipopolysaccharide, which is acute. We found that the responses were genetically controlled in mice and that low responsiveness is dominant (Maeda et al. 1991). Using 123 segregants of crosses between SWR/J (a high responder) and Mus spretus (a low responder), we analyzed the linkage between DT-APR responsiveness and the DNA polymerase chain reaction-simple sequence length polymorphism (PCR-SSLP) phenotype using 80 chromosome-specific microsatellite markers. We identified two loci (ltn1.1 and ltn1.2) responsible for DT-APR. ltn1.1 is closely linked to D3Mit11 on chromosome 3 and ltn1.2 to D11Nds9 on chromosome 11 (P <0.001). The linkage analysis also suggested that ltn1.2 is the major determinant for DT-APR. Correlation between lentinan-specific IL-6 mRNA expression (the late expression) controlled recessively and DT-APR induction suggests that the ltn1 loci control some process(es) of IL-6 expression in the regulation step before NF-IL6. |
